Intelligence · Patents
Patents expiring in 2033
Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.
- Patents
- 1,330
Quick answer
1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8377444
Therapeutic agent or preventive agent for osteoarthritis
granted -
US 8377959
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
granted -
US 8377965
Crystalline forms of a biphenyl compound
granted -
US 8377945
Small molecule inhibitors of spleen tyrosine kinase (SYK)
granted -
US 8377926
Aminopyridine kinase inhibitors
granted -
US 8377924
Protein kinase C inhibitors and uses thereof
granted -
US 8377872
Cyclic P3 tripeptide hepatitis C serine protease inhibitors
granted -
US 8377884
Variants of C-type natriuretic peptides
granted -
US 8377450
Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
granted -
US 8378107
Heteroaryl antagonists of prostaglandin D2 receptors
granted -
US 8377637
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P
granted -
US 8377966
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 8383589
Aegyptin and uses thereof
granted -
US 8383580
Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases
granted -
US 8383576
LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
granted -
US 8383388
Modified coagulation factor IX polypeptides and use thereof for treatment
granted -
US 8383133
Conjugates of Plasmodium falciparum surface proteins as malaria vaccines
granted -
US 8383380
Segmented polymers and their conjugates
granted -
US 8383132
Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
granted -
US 8383360
Methods of diagnosing and treating autism
granted -
US 8383102
Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
granted -
US 8383093
Subcutaneous delivery of poly(oxazoline) conjugates
granted -
US 8383817
Benztropine compounds and uses thereof
granted -
US 8383099
Adoptive cell therapy with young T cells
granted -
US 8383113
Anti-ADDL antibodies and uses thereof
granted -
US 8383583
Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
granted -
US 8383858
Processes and intermediates for preparing steric compounds
granted -
US 8383628
Pyridyl derivatives and their use as therapeutic agents
granted -
US 8383645
Stable laquinimod preparations
granted -
US 8383805
RNAi modulation of SCAP and therapeutic uses thereof
granted -
US 8383665
Immunomodulatory compositions
granted -
US 8383785
Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides
granted -
US 8383669
Crystalline form of a 3-phenoxymethylpyrrolidine compound
granted -
US 8383647
Quinoline derivative
granted -
US 8383633
Aminopyrimidines useful as kinase inhibitors
granted -
US 8383654
Heterocyclic antagonists of prostaglandin D2 receptors
granted -
US 8389759
Oligomer-anticholinergic agent conjugates
granted -
US 8391959
Composition for improving efficiency of drug delivery
granted -
US 8388930
Diagnosis and assessment of skeletal related disease using calcium 41
granted -
US 8389736
Compounds having activity in correcting mutant-CFTR processing and uses thereof
granted -
US 8389679
Targeted antimicrobial moieties
granted -
US 8389727
Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide
granted -
US 8389502
Stabilized steroid composition and method for its preparation
granted -
US 8389731
Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase
granted -
US 8389515
2,4-pyrimidinediamine compounds and prodrugs and their uses
granted -
US 8389478
Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory
granted -
US 8389231
Assays, method and compositions that exploit a mycobacterial iron acquistion pathway in cells
granted -
US 8388969
Interleukin-1 alpha antibodies and methods of use
granted
Frequently asked questions
How many pharma patents expire in 2033?
1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.